论文部分内容阅读
目的观察拉米夫定联合血浆置换法对慢性重型乙型病毒性肝炎患者生存率的影响。方法采用配对的回顾性队列研究方法,对2008年10月至2012年12月住院的慢性重型乙型病毒性肝炎患者,根据年龄、性别和病程3个变量对应用拉米夫定联合血浆置换法和常规内科综合治疗的患者进行匹配,比例为1∶1。对照组采用常规内科综合治疗,治疗组在此基础上加拉米夫定联合血浆置换治疗,随访并比较两组中位生存时间及生存率的差别。结果拉米夫定联合血浆置换治疗组中位生存时间为97d;对照组中位生存时间为31d,两组之间生存率有明显差异(P<0.01)。结论应用拉米夫定联合血浆置换治疗可提高慢性重型乙型病毒性肝炎患者的生存率。
Objective To observe the impact of lamivudine combined with plasma exchange on the survival rate of patients with chronic severe hepatitis B virus. Methods A matched retrospective cohort study was conducted to evaluate the efficacy and safety of lamivudine combined with plasma exchange in patients with chronic severe hepatitis B who were hospitalized from October 2008 to December 2012 according to age, sex and duration of disease And conventional medical treatment in patients with matching, the ratio of 1: 1. The control group was treated by conventional internal medicine. On the basis of this, the treatment group was treated with lamivudine combined with plasma exchange. The difference of median survival time and survival rate was compared between the two groups. Results The median survival time of lamivudine combined with plasma exchange was 97 days. The median survival time of control group was 31 days. There was significant difference between the two groups (P <0.01). Conclusion The application of lamivudine combined with plasma exchange can improve the survival rate of patients with chronic severe hepatitis B virus.